The Interleukin Network in Sepsis: From Cytokine Storm to Clinical Applications

Area of Science:

• Immunology
• Critical Care Medicine
• Pathophysiology

Background:

• Sepsis is a life-threatening condition caused by a dysregulated host response to infection, leading to organ dysfunction.
• Interleukins (ILs) are central mediators in sepsis pathogenesis, influencing both protective and detrimental immune responses.
• The cytokine storm, involving ILs, is a hallmark of sepsis, contributing significantly to morbidity and mortality.

Purpose of the Study:

• To review current knowledge on the role of interleukins (ILs) in sepsis pathophysiology.
• To highlight the potential of ILs as diagnostic/prognostic biomarkers for sepsis.
• To explore therapeutic strategies targeting IL pathways in sepsis management.

Main Methods:

• Analysis of recent clinical and experimental studies on key ILs (IL-1, IL-6, IL-10, IL-8, IL-12, IL-18, IL-17) in sepsis.
• Focus on mechanistic insights, prognostic significance, and therapeutic interventions.
• Evaluation of ILs' involvement in immune response, inflammation, and organ dysfunction.

Main Results:

• IL-1 and IL-6 are potent pro-inflammatory mediators; IL-6 is a validated prognostic biomarker.
• IL-10 acts as an anti-inflammatory cytokine but can lead to immunosuppression and secondary infections.
• Other ILs (IL-8, IL-12, IL-18, IL-17) contribute to neutrophil recruitment, immune cell activation, and organ injury.
• Targeted therapies (e.g., IL-1 receptor antagonist, IL-6 receptor blockade) show promise in specific sepsis patient groups.

Conclusions:

• Interleukins play a critical, dual role in sepsis immunopathology, mediating hyperinflammation and immunosuppression.
• ILs are valuable diagnostic and prognostic biomarkers, and context-dependent therapeutic targets.
• Precision immunomodulation and personalized medicine are essential for improving sepsis outcomes.